生产企业：Pila Pharma
XEN-D0501 is a potential first-in-class oral small molecule TRPV1 antagonist being developed by Pila Pharma for metabolic disease (obesity, type 2 diabetes), with potential applications in pain and other inflammatory indications such as erythromelalgia (EM).
XEN-D0501 is a potential first-in-class oral small molecule TRPV1 antagonist being developed by Pila Pharma for metabolic disease (obesity, type 2 diabetes), with potential applications in pain and other inflammatory indications such as erythromelalgia (EM).
共 3 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
